glp 1 for nash Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty liver disease? Sagimet's NASH drug-GLP-1 combo tops

Zepbound is a Food and Drug Administration (FDA)-approved medication on November 2023 for chronic weight management in adults who are obese or are overweight with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol

10.1111/dom.14089

Further, impaired tricarboxylic acid (TCA) cycle and oxidative phosphorylation lead to increased DNA damage and consequently more ROS due to mitochondrial dysfunction

Rehfeld, J

These symptoms are typically mild to moderate and often improve over time with gradual dose titration

Protein malnutrition, though less common, may occur in patients with severe appetite suppression or food aversions, potentially compromising muscle health and function over time